Lupin Limited has formally informed exchanges about a further delay in closing the acquisition of VISUfarma B.V., Netherlands, by its wholly-owned subsidiary, Nanomi B.V. Previously expected by February 28, 2026, the transaction remains ongoing. Completion is now anticipated in April 2026, pending the final satisfaction of specified closing conditions agreed upon in the definitive agreement.
Update on Strategic Acquisition Timeline
Lupin Limited provided an update regarding the definitive agreement signed for the acquisition of VISUfarma B.V., a company based in the Netherlands. This transaction is being undertaken by Nanomi B.V., the company’s wholly-owned subsidiary operating in the Netherlands.
Following previous intimations made on September 29, 2025, and December 30, 2025, the company confirms that the process of acquiring the entire share capital is still actively in progress.
Revised Closing Schedule
The expected completion date for the transaction has been revised. The acquisition was originally targeted for closure by February 28, 2026, contingent upon meeting all stipulated closing conditions.
The company now anticipates that the proposed transaction will be finalized in April 2026. This revised timeline is subject to the necessary satisfaction of all specific closing conditions detailed in the original agreement.
Corporate Compliance Confirmation
This information is being shared for necessary public disclosure and dissemination to the stock exchanges. The communication was authorized by AMIT KUMAR GUPTA, Company Secretary & Compliance Officer, dated February 27, 2026.
Source: BSE
